findmyKOL

Gary Lu, MD, PhD

Basic profile

Hematology / Oncology

ORCIDNone on fileNPI
RegionDenton, TX · South CentralSpecialtyHematology / OncologyFocusOncology
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2022Online presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Gary Lu is an Oncology physician. OpenAlex indexes 106 publications with 2,159 citations (h-index 25).

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
106publications

Distinct works indexed by OpenAlex.

2,159citations

Total citations across indexed works.

25h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
45companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

2600 Scripture St
Denton, TX 762014315

Telephone

940-382-1022

Provider last certified this registry record 24 May 2022.

View the NPPES registry record

Industry payments

45 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

View the CMS Open Payments record ↗

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Blood & clotting

    45.1%
    Erythropoiesis-stimulating Agent24.1%
    Darbepoetin alfa100%
    Part B, office-administered25 patients
    Parenteral Iron Replacement18.7%
    Iron sucrose100%
    Part B, office-administered36 patients

    + 2 more classes in this area

  • Cancer & immunology

    24.1%
    PD-1 inhibitor22.4%
    Pembrolizumab100%
    Part B, office-administered20 patients
    Nucleoside Metabolic Inhibitor1.1%
    Fluorouracil100%
    Part B, office-administered18 patients

    + 7 more classes in this area

  • Metabolism & gastrointestinal

    18.9%
    Other antiemetics15%
    Fosaprepitant100%
    Part B, office-administered22 patients
    Serotonin-3 Receptor Antagonist3.1%
    Palonosetron hcl60%Granisetron hydrochloride38%Ondansetron Hcl1%Ondansetron Odt1%
    Part D + Part B38 patients

    + 4 more classes in this area

Where care is delivered (Part B)0% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”